Sellas Life Sciences Group Inc (SLS)
Sector • Healthcare Industry • Major Pharmaceutical Preparations |
Industry • Major Pharmaceutical Preparations |
Sector • Healthcare |
News
SELLAS Boosts AML Treatment with Promising Phase 2a Data and FDA Fast Track Designation for SLS009
Sellas Life Sciences Group Focuses on Clinical Advancements Amid Executive Leadership Reorganization
SELLAS Life Sciences Group, Inc. Announces Public Offering: An Opportunity for Shareholders
Sellas Life Sciences Group Inc Shows Improvement in 2023 First Quarter Results, But Concerns Remain
announced operating loss of $-7.146 millions, in the most recent fiscal period
The Diminishing Returns have expanded more at the amid the financial period closing March 31 2022